Lipid Nanoparticle– tag –
-
Curapath Accelerates Advanced Therapeutics Development with GMP Manufacturing Services for Polymer & Lipid Nanoparticles for Nucleic Acid Delivery
Curapath | CPHI Online Global Overview Curapath is offering comprehensive CDMO services specializing in the formulation and scale-up of polymer and lipid nanoparticles for targeted nucleic acid delivery. The company provides GMP manufact... -
Pharmaceutical Formulation Development Soars with LNP-Delivered mRNA Vaccines, Yet Poor Drug-Like Properties (Solubility, Permeability, PK) Account for 10-15% of Development Failures
IntuitionLabs.ai Singapore Overview Pharmaceutical formulation development has increased in complexity and importance with the advent of lipid nanoparticle (LNP)-delivered messenger RNA (mRNA) vaccines. A 2010-2017 clinical trial data re... -
Roivant Sciences Receives $771.6 Million Settlement from Moderna Lawsuit, Enters Cross-Licensing Agreement for LNP and GalNAc Technologies
Stock Titan USA Overview Roivant Sciences announced it received a $771.6 million settlement from a lawsuit with Moderna. The settlement includes a comprehensive cross-licensing agreement where Moderna grants Genevant/Arbutus non-exclusiv... -
Serina Therapeutics Non-Exclusively Licenses POZ Polymer Technology for LNP Drug Delivery Formulations to Pfizer, Accelerating Clinical Development of Investigational Drug SER-252
Serina Therapeutics USA Overview Serina Therapeutics has entered a non-exclusive licensing agreement with Pfizer for its proprietary POZ polymer technology for lipid nanoparticle (LNP) drug delivery formulations. This partnership is part... -
Integrated LNP Composition and Ligand Targeting Dramatically Enhances Pancreatic Beta Cell-Directed RNA Delivery
ACS Nano USA Overview Engineering lipid nanoparticles (LNPs) through integrated compositional and ligand targeting dramatically enhances pancreatic beta cell-directed RNA delivery. Systematically varying the species and molar ratios of t... -
Intellia Therapeutics Advances CRISPR Gene Therapy Pipeline, Including NTLA-2002 for HAE
Tracxn USA Overview Intellia Therapeutics is a public company advancing therapeutics based on CRISPR/Cas9 technology, with its lead candidate, NTLA-2002, an investigational CRISPR therapy for hereditary angioedema (HAE). The company also... -
New CAR-T Engineering Strategies Target Solid Tumor Barriers: Leveraging Real-World Data & Manufacturing Innovations
ecancer International Overview Novel engineering strategies for CAR-T cell therapy against solid tumors are focusing on enhancing T-cell anti-tumor activity and overcoming microenvironmental barriers. Recent clinical results, such as int... -
USC Viterbi Engineers Develop Ultrasound-Guided SHIFTERS Technology to Reprogram Solid Tumors for CAR-T Efficacy
USC Viterbi School of Engineering USA Overview Researchers at the USC Viterbi School of Engineering have developed a novel technology called SHIFTERS to enable CAR-T cells to effectively target solid tumors. This method uses focused ultr... -
LNP-Delivered Gene Editing Platform Targets Hepatic Lipid Metabolic Disorders for Durable, Single-Intervention Correction
Ace Therapeutics USA Overview This platform focuses on lipid nanoparticle (LNP)-delivered gene editing for heritable lipid disorders, aiming for durable, single-intervention correction of disease-driving genes in the liver. It integrates... -
RNA Therapeutics Advance with Delivery Challenges: mRNA Vaccines, siRNAs, and ASOs Drive Disease Treatment
Facebook (Ambry Genetics) USA Overview Recent publications highlight the profound impact of RNA-based therapeutic modalities, including mRNA vaccines, siRNAs, and ASOs, in treating viral infections, genetic disorders, and cancer. However...
